Lanthio grants Tarix exclusive license to peptide for acute lung injury
This article was originally published in Scrip
Executive Summary
Dutch peptide drug company, Lanthio Pharma has granted Tarix Pharmaceuticals an exclusive licence to its lanthionine-stabilised angiotensin-(1-7) agonistic peptide. The commercial terms include milestone payments and royalties, Lanthio said, adding that Tarix will finance further product development.